A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Deal Date | Stages | Upfront Cash ($M) | Upfront Equity ($M) | Deal Size ($M) | Upfront Share (%) | R&D | Client | Deal Types | Deal Subject | Contracts | PRs | Deal Source | Exclusivity | Licensor Category | Licensee Category | Diseases | Indications | Technologies | Sub Technologies | Territory | Sub-Territory | MOA Category | Molecular Target | Drug Mode of Action | Profit Split (%) | Financial Term Explanations |
2 | 05/2019 | Discovery | Bicycle Therapeutics | Dementia Discovery Fund | Option, Research | Bicyclic peptides for dementia with option to jointly launch company to develop identified compounds | Yes | PR | Central Nervous System | Dementia | Peptides | ||||||||||||||||
3 | 05/2019 | Phase I, Orphan Indication | Forty Seven | AstraZeneca, Acerta Pharma | Research | Evaluation of 5F9 combined with rituximab and acalabrutinib for Large B-cell lymphoma | Yes | PR | 2013-19 IPOs | Top Pharma | Cancer | Lymphoma | Monoclonals, Synthetics | Small Molecule | Kinase, Immuno-Oncology | CD20, bruton agammaglobulinemia tyrosine kinase (BTK) | Inhibitor | ||||||||||
4 | 05/2019 | Discovery | 50.00 | 5.00 | Goldfinch Bio | Gilead | Co-Development, Co-Promotion, Equity, License, Option, Research | Kidney Genome Atlas to identify and validate targets for diabetic nephropathy, rare kidney diseases | Yes | PR | Major Biotech | Renal | Other Renal | Worldwide | $54M to support development of the KGA platform for DKD | $1.95 billion in research, development, regulatory and commercial milestones for the first five programs | ||||||||||||
5 | 05/2019 | Discovery | Harbour BioMed | Chia Tai Tianqing Pharmaceutical | Co-Development, License | Fully human antibody therapies for multiple oncology and immunology therapeutic targets | Yes | PR | Autoimmune/Inflammatory, Cancer | Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer | Monoclonals, Transgenics | Human Abs | |||||||||||||||
6 | 05/2019 | Preclinical | Iconic Therapeutics | Exelixis | License, Option | ICON-2 antibody-drug conjugate targeting tissue factor to treat solid tumors | Yes | PR | Exclusive | Cancer | Solid Tumors | Monoclonals | Conjugates | ||||||||||||||
7 | 05/2019 | Discovery | Kymera Therapeutics | Vertex | Equity, License, Option, Research | Pegasus drug discovery platform to advance small molecule protein degraders against multiple targets | Yes | PR | Major Biotech | Synthetics | Small Molecule | $70M upfront including an equity investment | Kymera is eligible to receive in excess of $1 billion in research, development, regulatory, and commercial milestones for up to six programs | tiered royalties | |||||||||||||||
8 | 05/2019 | Preclinical | Ligand | Cumulus Oncology | License | VER250840 Chk1 kinase inhibitor for cancer | Yes | PR | Exclusive | Cancer | Broad Focus Cancer | Synthetics | Small Molecule | Worldwide | Tiered royalties in the mid-to-high single digit range | Ligand will receive an upfront license fee, and is eligible to receive over $76M of milestone payments | ||||||||||||
9 | 05/2019 | Phase III | 17.50 | 150.00 | 11.67 | MediWound | Vericel | License, Supply | NexoBrid topical wound healing product for severe burns in North America | Yes | PR | Exclusive | 2013-19 IPOs | Dermatologic | Burns | Drug Delivery, Peptides | Topical | NAFTA | All NAFTA Countries | Tiered royalties ranging from high single-digit to low double-digit percentages | $7.5M upon U.S. BLA approval | |||||||
10 | 05/2019 | Preclinical | Nationwide Childrens Hospital | Sarepta Therapeutics | License, Option | Calpain 3 (CAPN-3) gene therapy for Limb-girdle muscular dystrophy type 2A | Yes | PR | Research Institution | Other/Miscellaneous | Genetic Disorders | Oligonucleotides | Gene Therapy | Gene Therapy | |||||||||||||
11 | 05/2019 | Preclinical | Numab | CStone Pharmaceuticals | License, Research | ND021 PD-L1/4-1BB/HSA monovalent tri-specific scMATCH3 for cancer in China, South Korea, Singapore | Yes | PR | Exclusive | Cancer | Broad Focus Cancer | Monoclonals | Asia | Immuno-Oncology | tumor necrosis factor (TNF) receptor superfamily member 9 (TNFRSF9) (CD137) (4-1BB), programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) | Agonist, Inhibitor | CStone will fund the research and development of ND021 up to completion of an initial Phase Ib clinical trial | ||||||||||
12 | 05/2019 | Phase III | 2.00 | 2.00 | 51.50 | 7.77 | Onconova | HanX Biopharmaceuticals | License, Supply | Rigosertib (RAS effector) for myelodysplastic syndromes in China | Yes | PR | Exclusive | 2013-19 IPOs | Cancer | Leukemia, Other Cancer | Synthetics | Small Molecule | Asia | China | $2M in Onconova shares purchased at a premium | HanX will place $2M in escrow in local currency for rigosertib clinical development expenses in China | Tiered royalties up to double digits | $45.5M in regulatory, development. and sales milestones | ||||||
13 | 05/2019 | Preclinical | Parvus Therapeutics | Roche, Genentech | License | Navacim therapeutics for inflammatory bowel disease, autoimmune liver diseases and celiac disease | Yes | PR | Top Pharma | Autoimmune/Inflammatory, Gastrointestinal, Liver & Gallbladder Diseases | IBD - Crohn's Disease, IBD - Other, IBD - Ulcerative Colitis, Other Autoimmune/Inflammatory, Other Liver & Gallbladder Diseases | Worldwide | |||||||||||||||
14 | 05/2019 | Discovery | Skyhawk Therapeutics | Takeda | License, Research | SkySTAR platform to discover small molecules RNA splicing modifiers for neurodegenerative diseases | Yes | PR | Exclusive | Top Pharma | Central Nervous System | Broad Focus Central Nervous System | Synthetics | Small Molecule | Worldwide | ||||||||||||
15 | 05/2019 | Phase III | Takeda | Phathom Pharmaceuticals | Equity, License | Vonoprazan for acid-related disorders and H. pylori in the US, Europe and Canada | Yes | PR | Exclusive | Top Pharma | Gastrointestinal, Infectious-Bacterial | Esophageal Reflux, Other Infectious-Bacterial | Synthetics | Small Molecule | Europe, NAFTA | All European Countries, Canada, US | |||||||||||
16 | 05/2019 | Discovery | 10.00 | Transgene | AstraZeneca | Co-Development, License, Option, Research | Up to five engineered oncolytic vaccinia virus candidates for immuno-oncology indications | Yes | PR | Exclusive | Top Pharma | Cancer | Broad Focus Cancer | $3M in preclinical milestones | Undisclosed option payment, plus additional development and commercial milestones for each product | |||||||||||||
17 | 05/2019 | Phase I, Orphan Indication | X4 Pharmaceuticals | Leukemia & Lymphoma Society | Development | Therapy Acceleration Program funds to develop mavorixafor in Waldenstrom’s macroglobulinemia | Yes | PR | Research Institution | Cancer | Lymphoma | Synthetics | Small Molecule | ||||||||||||||
18 | 04/2019 | Discovery | Adagene | ADC Therapeutics | License, Research | Masked antibody combined with pyrrolobenzodiazepine cytotoxic payload technology for solid tumors | Yes | PR | Cancer | Solid Tumors | Monoclonals | Conjugates | |||||||||||||||
19 | 04/2019 | Discovery | 400.00 | 400.00 | 1,625.00 | 49.23 | Alnylam | Regeneron Pharmaceuticals | Co-Development, Equity, License, Option, Research | RNAi therapeutics for ophthalmic & CNS indications, programs targeting genes expressed in the liver | Yes | PR | Exclusive | Major Biotech | Major Biotech | Central Nervous System, Liver & Gallbladder Diseases, Ophthalmic | Broad Focus Central Nervous System, Broad Focus Ophthalmic | Oligonucleotides | RNAi | Worldwide | 50.00 | 4.44 million common shares @ $90.00/sh | For each program, Alnylam will receive $2.5M at program initiation and an additional $2.5 million at lead candidate, for up to $30M in annual
discovery funding | $200M in near-term milestones for the eye and CNS programs | $325M in sales milestones for cemdisiran | low double-digit to 20% royalty in Eye Field | $150M in agg milestones for Eye Field targets | 50% PS in CNS & Liver Fields | |||||
20 | 04/2019 | Phase I | Ascentage Pharma | Shanghai Junshi Biosciences | Research | Evaluation of APG-1387 combined with Toripalimab for solid and hematological tumors in China | Yes | PR | Cancer | Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors | Monoclonals, Synthetics | Humanized Abs, Small Molecule | Asia | China | Immuno-Oncology | apoptosis protein, programmed cell death 1 (PD-1) (PDCD1) (CD279) | Inhibitor | ||||||||||
21 | 04/2019 | Discovery | Atomwise | Drugs for Neglected Diseases Initiative | Research | Atomnet AI-based screening technology to identify compounds for Chagas disease | Yes | PR | Research Institution | Infectious-Miscellaneous | Parasitic-Miscellaneous | Screening | |||||||||||||||
22 | 04/2019 | Discovery | 20.00 | 15.00 | 450.00 | 7.78 | Avidity Biosciences | Lilly | Equity, License, Research | Antibody-oligonucleotide conjugates to treat immune diseases | Yes | PR | Top Pharma | Autoimmune/Inflammatory | Monoclonals, Oligonucleotides | Conjugates | Worldwide | Tiered royalties ranging from the mid-single to low-double digits | $405M per target for development, regulatory and commercialization milestones | |||||||||
23 | 04/2019 | Phase I | Bayer | Hope Medicine | License | Prolactin receptor antibody for hair loss, endometriosis, chronic disease indications | Yes | PR | Exclusive | Top Pharma | Genitourinary/Gynecologic, Other/Miscellaneous | Hair Growth, Other Genitourinary/Gynecologic | Monoclonals | Human Abs | Worldwide | ||||||||||||
24 | 04/2019 | Preclinical | 20.00 | BioAtla | BeiGene | Co-Development, License | CAB CTLA-4 antibody (BA3071) for cancer | Yes | PR | 2013-19 IPOs | Cancer | Broad Focus Cancer | Monoclonals | Worldwide | Immuno-Oncology | cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (CD152) | BeiGene is responsible for all costs in Asia excluding Japan, Australia and New Zealand | Undisclosed early clinical milestones, plus up to $249M in additional development and regulatory milestones globally and commercial milestones | ||||||||||
25 | 04/2019 | Discovery | Bio-Techne | Elpiscience BioPharma | License, Research | Antibody immunotherapies for cancer | Yes | PR | Cancer | Monoclonals | |||||||||||||||||
26 | 04/2019 | Discovery | Calixar | Regeneron Pharmaceuticals | License | Antibodies against undisclosed target in multiple therapeutic areas | Yes | PR | Major Biotech | Monoclonals | |||||||||||||||||
27 | 04/2019 | Discovery | Calixar | Thermo Fisher Scientific | License, Research | Expression systems to produce membrane protein targets for drug discovery | Yes | PR | |||||||||||||||||||
28 | 04/2019 | Phase II, Orphan Indication | Dermelix Biotherapeutics | EspeRare | Development | DMX-101 in utero protein replacement therapy for X- Linked Hypohidrotic Ectodermal Dysplasia | Yes | PR | Dermatologic, Other/Miscellaneous | Genetic Disorders, Other Dermatologic | Recombinant DNA | ||||||||||||||||
29 | 04/2019 | Discovery | Editas Medicine | BlueRock Therapeutics | Cross-License, Research | Combined genome editing and cell therapy technologies to discover cell medicines | Yes | PR | Non-exclusive | 2013-19 IPOs | Autoimmune/Inflammatory, Cancer, Cardiovascular, Central Nervous System | Cell Therapy - Stem Cells/Factors | |||||||||||||||
30 | 04/2019 | Phase I, Orphan Indication | Emory University | Moleculin | Research | Phase I evaluation of WP1066 in children with recurrent or refractory malignant brain tumors | Yes | PR | Research Institution | 2013-19 IPOs | Cancer | Brain | Synthetics | Small Molecule | Immuno-Oncology | ||||||||||||
31 | 04/2019 | Phase I | FameWave | Bristol-Myers Squibb | Research | Phase I/II evaluation of CM-24 combined with nivolumab for non-small cell lung cancer | Yes | PR | Top Pharma | Cancer | Lung | Monoclonals | Human Abs, Humanized Abs | Immuno-Oncology | programmed cell death 1 (PD-1) (PDCD1) (CD279) | Antagonist | |||||||||||
32 | 04/2019 | Phase I, Orphan Indication | 7.50 | 115.00 | 6.52 | Fibrocell Science | Castle Creek Pharmaceuticals | Co-Development, License | FCX-007 gene therapy for recessive dystrophic epidermolysis bullosa in the US | Yes | PR | Exclusive | Dermatologic, Other/Miscellaneous | Genetic Disorders, Other Dermatologic | Oligonucleotides | Gene Therapy | NAFTA | US | Gene Therapy | collagen type VII | Replacer | 30.00 | $75M consisting of $25M when FCX-007 achieves $250M in cumulative net sales and an additional $50M upon attaining $750M in cumulative net sales | Castle Creek will pay for all development and manufacturing expenses up to $20M prior to BLA filing with the FDA and is responsible for 70% of excess costs above the $20M. | $2.5M for the first patient enrolled in the Phase 3 clinical trial and $30M upon BLA approval and commercial readiness. | Fibrocell will receive a 30% share of the gross profits from FCX-007 sales. | ||||
33 | 04/2019 | Discovery | Forge Therapeutics | Basilea Pharmaceutica | License, Research | Blacksmith metalloenzyme chemistry platform to identify antibiotics against two targets | Yes | PR | Infectious-Bacterial | $167M in development and sales milestones/target | |||||||||||||||||
34 | 04/2019 | Phase I, Orphan Indication | GlaxoSmithKline | Fulcrum Therapeutics | Equity, License | Losmapimod p38 kinase inhibitor for facioscapulohumeral muscular dystrophy | Yes | PR | Exclusive | Top Pharma | Other/Miscellaneous | Genetic Disorders | Synthetics | Small Molecule | Worldwide | Anti-Inflammatory | mitogen-activated protein kinase 14 (MAPK14) (p38) (p38-alpha) (p38MAPK) | Inhibitor | |||||||||
35 | 04/2019 | Phase III | Global Alliance for TB Drug Development | Mylan | License | Pretomanid as part of BPaL and BPaMZ regimens for tuberculosis | Yes | PR | Research Institution | Infectious-Bacterial | Tuberculosis | Synthetics | Small Molecule | Worldwide | Antibacterial | nitric oxide (NO) | Stimulant | ||||||||||
36 | 04/2019 | Lead Molecule | HitGen | Kaken Pharmaceutical | License | Small molecule leads against undisclosed target | Yes | PR | Exclusive | Synthetics | Small Molecule | ||||||||||||||||
37 | 04/2019 | Discovery | Indivumed | Evotec AG | License, Research | Indivutype database combined with PanHunter bioinformatics analysis platform for colorectal cancer | Yes | PR | Cancer | Colorectal | Bioinformatics, Monoclonals, Synthetics | Small Molecule | |||||||||||||||
38 | 04/2019 | Preclinical | InflamaCORE | Variant Pharmaceuticals | License | IC 100 inflammasome inhibitor for inflammatory diseases | Yes | PR | Exclusive | Autoimmune/Inflammatory | Monoclonals | Worldwide | Gene Therapy | ||||||||||||||
39 | 04/2019 | Discovery | 15.00 | 1,050.00 | 1.43 | Insitro | Gilead | Co-Development, Co-Promotion, License, Option, Research | Insitro Human platform to create disease models of NASH and identify up to five targets | Yes | PR | Major Biotech | Liver & Gallbladder Diseases | Fatty Liver | Genomics | Low double-digit tiered royalties | Near term payments up to $35M based on operational milestones | $200M in development, regulatory and commercial milestones for each of the five Gilead targets | |||||||||||
40 | 04/2019 | Phase I, Preclinical, Discovery | 10.00 | Medigene | Roivant Sciences, Cytovant Sciences | Development, License, Research | Four programs including TCR immunotherapy targeting NY-ESO-1 & DC vaccine targeting WT-1 and PRAME | Yes | PR | Exclusive | Cancer | Broad Focus Cancer | Cell Therapy - Stem Cells/Factors, Vaccines | Asia | China, Japan, Other Asian | Cytovant will reimburse all R&D costs incurred by Medigene | Low double-digit royalties | Development, regulatory, and commercial milestones in excess of $1 billion for the four products across multiple indications | |||||||||||
41 | 04/2019 | Phase II | Mitsubishi, Mitsubishi Tanabe Pharma | Bausch Health, Salix Pharmaceuticals | License | MT-1303 (amiselimod) for IBD, ulcerative colitis, autoimmune diseases WW ex-Japan | Yes | PR | Exclusive | Japanese Pharma | Mid Tier Pharma | Autoimmune/Inflammatory, Gastrointestinal | IBD - Other, IBD - Ulcerative Colitis | Synthetics | Small Molecule | Africa, Asia, Europe, Middle East, NAFTA, South America | All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia | Immunosuppresant | sphingosine 1-phosphate (S1P) receptor | Antagonist | |||||||
42 | 04/2019 | Preclinical | Monash University | Qpex Biopharma | License | Polymyxin antimicrobials including colistin for drug-resistant gram-negative pathogens | Yes | Exclusive | Research Institution | Infectious-Bacterial | Broad Focus Infectious-Bacterial | Synthetics | Small Molecule | ||||||||||||||
43 | 04/2019 | Preclinical, Orphan Indication | Nationwide Childrens Hospital | Audentes Therapeutics | License, Research | AT702 AAV-antisense candidate for Duchenne muscular dystrophy and myotonic dystrophy | Yes | PR | Exclusive | Research Institution | 2013-19 IPOs | Other/Miscellaneous | Genetic Disorders | Oligonucleotides | Antisense/Triple helix, Gene Therapy | gene therapy adeno-associated viral vectors (AAV) | |||||||||||
44 | 04/2019 | Phase III | 5.00 | PharmaMar | Luye Pharma | License | Lurbinectedin (Zepsyre) for lung cancer in China | Yes | PR | Cancer | Lung | Synthetics | Small Molecule | Asia | China | DNA/RNA Disruption | RNA polymerase | Inhibitor | Double digit royalties | ||||||||
45 | 04/2019 | Phase I, Formulation | 22.00 | 22.00 | 100.00 | Pulmatrix | Cipla, Cipla Technologies | Co-Development, Letter of Intent, License | Pulmazole (inhaled iSPERSE formulation of itraconazole) for allergic bronchopulmonary aspergillosis | Yes | Yes | SEC Full | 2013-19 IPOs | Infectious-Miscellaneous | Fungal | Drug Delivery, Synthetics | Other, Small Molecule | Worldwide | Antifungal | 14 alpha-sterol demethylase | Inhibitor | 50.00 | |||||
46 | 04/2019 | Phase II | Rexahn Pharmaceuticals | BioSense Global | License | RX-3117 for pancreatic cancer and other cancers in China | Yes | PR | Exclusive | Cancer | Pancreatic | Synthetics | Small Molecule | Asia | China | DNA/RNA Disruption | DNA synthesis, RNA synthesis | Inhibitor | Tiered low double digit to mid teen royalties | $226M in development, regulatory and commercial milestones | ||||||||
47 | 04/2019 | Phase I | Tessa Therapeutics | Merck | Research | Phase Ib/II evaluation of TT12 cell therapy combined with Keytruda in cervical cancer | Yes | PR | Top Pharma | Cancer | Cervical | Cell Therapy - Stem Cells/Factors, Monoclonals | Humanized Abs | Cell Therapy, Immuno-Oncology | programmed cell death 1 (PD-1) (PDCD1) (CD279) | Antagonist | |||||||||||
48 | 04/2019 | Discovery | twoXAR | SK Biopharmaceuticals | License | AI-based discovery technology to identify drug candidates for lung cancer | Yes | PR | Exclusive | Cancer | Lung | Worldwide | |||||||||||||||
49 | 04/2019 | Discovery | Velabs Therapeutics | Chiome Bioscience | License, Research | Microfluidic screening technology to discover modulatory and functional antibodies against GPCRs | Yes | PR | Monoclonals, Screening | Worldwide | |||||||||||||||||
50 | 04/2019 | Discovery | Xencor | Astellas Pharma | License | Bispecific antibodies against undisclosed cancer target | Yes | PR | Exclusive | 2013-19 IPOs | Japanese Pharma | Cancer | Monoclonals | Bispecific | Worldwide | ||||||||||||
51 | 03/2019 | Phase I | 25.00 | 650.00 | 3.85 | Affibody AB | Alexion | Co-Development, Co-Promotion, License, Option | ABY-039 anti-FcRn Affibody for rare Immunoglobulin G-mediated autoimmune diseases | Yes | PR | Major Biotech | Autoimmune/Inflammatory | Monoclonals | Immuno-Oncology | Fc fragment of IgG, receptor, transporter, alpha (FCGRT) (FCRN) | Tiered low double-digit royalties | $625M in development and sales milestones | ||||||||||
52 | 03/2019 | Discovery | 10.00 | 475.00 | 2.11 | Ambrx | BeiGene | License, Option, Research | Expanded Genetic Code platforms to discover biologic drug candidates for cancer | Yes | PR | 2013-19 IPOs | Cancer | Broad Focus Cancer | Monoclonals | Conjugates | Worldwide | Ambrx will receive $19M if BeiGene elects to initiate additional programs, and up $446M in development, regulatory, and sales-based
milestones for all programs | |||||||||
53 | 03/2019 | Phase II | 1.00 | 9.00 | 11.11 | Aslan Pharmaceuticals | BioGenetics | License | ASLAN003 for AML & solid tumors in S Korea | Yes | SEC Redacted | Exclusive | 2013-19 IPOs | Cancer | Solid Tumors | Synthetics | Small Molecule | Asia | Other Asian | Enzyme Inhibitor | dihydroorotate dehydrogenase (DHODH) | Inhibitor | Double digit royalties to mid-20s, per Aslan's 2018 20-F | $8M in agg milestones, per Aslan's 2018 20-F | ||||
54 | 03/2019 | Phase III | 1,350.00 | 6,900.00 | 19.57 | Daiichi Sankyo | AstraZeneca | Co-Development, Co-Promotion, License, Supply | Trastuzumab deruxtecan (DS-8201) antibody-drug conjugate for HER2-positive cancers WW ex-Japan | Yes | PR | Japanese Pharma | Top Pharma | Cancer | Broad Focus Cancer | Monoclonals | Conjugates | Africa, Asia, Europe, Middle East, NAFTA, South America | All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia | Receptor | DNA topoisomerase I, epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2) | Antagonist, Inhibitor | $1.35 billion half of which is due upon execution, with the remainder payable 12 months later | $3.8 billion in regulatory milestones | ||||
55 | 03/2019 | Discovery | Enamine | Lundbeck A/S | License, Research | REAL database to support drug discovery and identify hit series in multiple research programs | Yes | PR | Mid Tier Pharma | Screening | |||||||||||||||||
56 | 03/2019 | Discovery | Evotec AG | The Mark Foundation for Cancer Research | Research | Funding to advance oncology therapeutics based on TargetAlloMod drug discovery platform | Yes | PR | Cancer | Synthetics | Small Molecule | ||||||||||||||||
57 | 03/2019 | Discovery | 25.00 | Exscientia | Celgene | License, Research | Centaur Chemist AI-based platform to discover small molecules for cancer and autoimmune indications | Yes | PR | Major Biotech | Autoimmune/Inflammatory, Cancer | Synthetics | Small Molecule | ||||||||||||||
58 | 03/2019 | Discovery | HitGen | Almirall | License, Research | DNA encoded chemical libraries to discover small molecule leads against dermatology targets | Yes | PR | Mid Tier Pharma | Dermatologic | Dermatitis | Screening, Synthetics | Small Molecule | ||||||||||||||
59 | 03/2019 | Discovery | HitGen | Sun Pharma Advanced Research Company | License, Research | DNA encoded chemical libraries to discover small molecule leads against undisclosed targets | Yes | PR | Screening, Synthetics | Small Molecule | |||||||||||||||||
60 | 03/2019 | Phase II | Idera Pharmaceuticals | Bristol-Myers Squibb | Co-Development | Tilsotolimod (TLR agonist) with Yervoy (ipilimumab) and Opdivo (nivolumab) for solid tumors | Yes | SEC Redacted | Non-exclusive | Top Pharma | Cancer | Solid Tumors | Synthetics | Small Molecule | Immuno-Oncology | toll-like receptor 9 (TLR9), cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (CD152) | Agonist, Inhibitor | ||||||||||
61 | 03/2019 | Discovery | Iktos | Merck KGaA | License | Generative modelling artificial intelligence technology for three drug discovery projects | Yes | PR | Top Pharma | ||||||||||||||||||
62 | 03/2019 | Preclinical | 40.00 | 605.00 | 6.61 | ImmuNext | Lilly | License, Research | Preclinical target to treat autoimmune disorders by regulating immune cell metabolism | Yes | PR | Exclusive | Top Pharma | Autoimmune/Inflammatory | Monoclonals | Worldwide | Tiered royalties ranging from the mid-single to low-double digits | $565M in development and commercialization milestones, | ||||||||||
63 | 03/2019 | Phase I | ImmunoBiology | China National Biotec Group, Lanzhou Institute of Biological Product | Co-Development, License | PnuBioVax vaccine against pneumococcal infection in China | Yes | PR | Infectious-Bacterial | Other Infectious-Bacterial | Vaccines | Asia | China | ||||||||||||||
64 | 03/2019 | Phase II | Lilly | Transcenta, Hangzhou Just Biotherapeutics | Equity, License | Portfolio of bone disease biotherapeutics including blosozumab for osteoporosis in China | Yes | PR | Top Pharma | Bone Disease | Osteoporosis | Monoclonals | Humanized Abs | Asia | China | Antibody | sclerostin (SOST) | Inhibitor | |||||||||
65 | 03/2019 | Phase II | Lilly | Transcenta | Equity, License | Biotherapeutics including Blosozumab for bone diseases in China | Yes | PR | Exclusive | Top Pharma | Bone Disease | Osteoporosis | Monoclonals | Humanized Abs | Asia | China | Antibody | sclerostin (SOST) | Inhibitor | ||||||||
66 | 03/2019 | Discovery, Formulation | NapaJen Pharma | Astellas Pharma | License, Research | Schizophyllan delivery technology to develop oligonucleotide therapeutic for undisclosed indications | Yes | PR | Japanese Pharma | Drug Delivery, Oligonucleotides | Other | ||||||||||||||||
67 | 03/2019 | Phase I, Orphan Indication | ProQR Therapeutics | Wings Therapeutics | Equity, License | Spin out of Wings Therapeutics to develop RNA therapies for dystrophic epidermolysis bullosa | Yes | PR | 2013-19 IPOs | Dermatologic, Other/Miscellaneous | Genetic Disorders, Other Dermatologic | Oligonucleotides | |||||||||||||||
68 | 03/2019 | Phase II | Takeda | Petra Pharma | License | Serabelisib & two PI3Kalpha-specific inhibitors for all indications ex-undisclosed rare diseases | Yes | PR | Top Pharma | Synthetics | Small Molecule | Worldwide | |||||||||||||||
69 | 03/2019 | Discovery | Trianni | San Diego Biomedical Research Institute | License | Trianni Mouse monoclonal antibody discovery platform to support HIV vaccine research | Yes | PR | Infectious-Viral | Human Immunodeficiency Virus/HIV | Monoclonals, Transgenics | Human Abs, Transgenic mice | |||||||||||||||
70 | 03/2019 | Discovery | twoXAR | Ono Pharmaceutical | License, Research | AI-platform to identify drug candidates for undisclosed neurological disease | Yes | PR | Exclusive | Central Nervous System | Screening | Worldwide | |||||||||||||||
71 | 03/2019 | Preclinical, Orphan Indication | 51.00 | 686.80 | 7.43 | Vivet Therapeutics | Pfizer | Equity, License, Option | VTX-801 gene therapy for Wilson disease, acquisition of 15% equity stake with option to acquire 100% | Yes | PR | Top Pharma | Liver & Gallbladder Diseases, Other/Miscellaneous | Genetic Disorders, Other Liver & Gallbladder Diseases | Oligonucleotides | Gene Therapy | Gene Therapy | €45 million (US$51 million) | €560 million (US$635.8 million) inclusive of the option exercise payment and clinical, regulatory, and commercial milestones | |||||||||
72 | 03/2019 | Preclinical | 340.00 | Wellcome Trust, King's College London | Merck | License | Non-opioid treatments targeting HCN2 for chronic neuropathic pain | Yes | PR | Research Institution | Top Pharma | Central Nervous System | Pain | ||||||||||||||
73 | 03/2019 | Discovery | 25.00 | 15.00 | Zealand Pharma | Alexion | Equity, License, Option, Research | Subcutaneously delivered peptide therapies against up to four complement pathway targets | Yes | PR | Exclusive | 2013-19 IPOs | Major Biotech | Peptides | Worldwide | $495M in sales milestones for lead target | High single- to low double-digit royalties | $115M in development milestones for lead target | Option fee of $15 million for each of the three subsequent targets, plus additional development and sales milestones and royalty payments at a reduced price to the lead target. | |||||||||||
74 | 02/2019 | Phase I | 3-V Biosciences | Ascletis Pharma | Equity, License | TVB-2640 (ASC40) FASN inhibitor for non-alcoholic steatohepatitis in China | Yes | PR | Exclusive | Liver & Gallbladder Diseases | Fatty Liver | Synthetics | Small Molecule | Asia | China | Enzyme Inhibitor | fatty acid synthase (FASN) (FAS) | Inhibitor | |||||||||
75 | 02/2019 | Discovery | AbCellera | Novartis | License, Research | Single-cell screening technology to discover mAbs against up to 10 targets | Yes | PR | Top Pharma | Monoclonals | |||||||||||||||||
76 | 02/2019 | Discovery | Abpro | Chia Tai Tianqing Pharmaceutical, NJCTTQ | License, Research | DiversImmune antibody platform to generate bispecific therapeutics for immuno-oncology indications | Yes | PR | Exclusive | Cancer | Broad Focus Cancer | Monoclonals | Bispecific | Asia | China | $60 million in near-term R&D funding | Abpro eligible to receive up to $4 billion | |||||||||||
77 | 02/2019 | Phase II, Orphan Indication | 2.00 | 13.00 | 15.38 | Aslan Pharmaceuticals | BioGenetics | License | Varlitinib (ASLAN001 pan_HER inhibitor) for biliary tract cancer in S Korea | Yes | SEC Redacted | Exclusive | 2013-19 IPOs | Cancer | Other Cancer | Synthetics | Small Molecule | Asia | Other Asian | Receptor | epidermal growth factor receptor (EGFR) (ERBB) (ERBB1) (HER1) (PIG61) (mENA), epidermal growth factor receptor type 2 (HER2) (ERBB2) (receptor tyrosine-protein kinase erbB-2) | Inhibitor | Double digit royalties up to mid-20s, per Aslan's 2018 20-F | $11M in agg milestones, per Aslan's 2018 20-F | ||||
78 | 02/2019 | Phase II | 30.00 | 195.00 | 15.38 | Dermira | Almirall | Co-Development, License, Option, Supply | Lebrikizumab (IL-13 ab) for atopic dermatitis in Europe | Yes | Yes | SEC Redacted | Exclusive | 2013-19 IPOs | Mid Tier Pharma | Dermatologic | Broad Focus Dermatologic, Dermatitis | Monoclonals | Humanized Abs | Europe | European Union, Other European, Scandinavia | Double-digit royalties to low 20s, per Dermira's 3Q19 | $50M option exercise fee; $30 upon initiation of certain Phase 3 clinical studies and up to $85 upon the achievement of regulatory milestones and the first commercial sale of lebrikizumab in Europe. | CON sales milestones | |||||
79 | 02/2019 | Phase III, Formulation | 86.00 | Foresee Pharmaceuticals | Accord Healthcare | License | FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) for prostate cancer | Yes | PR | Exclusive | Cancer | Prostate | Drug Delivery, Peptides | Controlled Release | Africa, Asia, Europe, NAFTA, South America | All African Countries, All European Countries, All South American Countries, Australia, Canada, India, Mexico, New Zealand, Other Asian, Southeast Asia | Receptor | gonadotropin-releasing hormone receptor (GnRH) | Agonist | $86M in upfront, regulatory milestones and sales milestones | |||||||
80 | 02/2019 | Preclinical | IFM Therapeutics | IFM Due | License | Spinout of IFM Due to develop cGAS/STING antagonists for inflammatory and autoimmune diseases | Yes | PR | Autoimmune/Inflammatory | Synthetics | Small Molecule | ||||||||||||||||
81 | 02/2019 | Phase II | 342.00 | 4,200.00 | 8.14 | Merck KGaA | GlaxoSmithKline | Co-Development, Co-Promotion, License | M7824 (bintrafusp alfa) bifunctional fusion protein for cancer | Yes | PR | Top Pharma | Top Pharma | Cancer | Broad Focus Cancer | Monoclonals, Recombinant DNA | Bispecific | Worldwide | Protein | programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) | Inhibitor | €300 million (US$342M) | Up to €500 million (US$570M) in development milestone payments related to data from the M7824 lung cancer program | Up to €2.9 billion (US$3.3 billion) in approval and commercial milestones | |||||
82 | 02/2019 | Phase III, Formulation | 1.70 | 56.00 | 3.04 | Moberg Pharma | Bayer | License, Supply | MOB-015 topical formulation of terbinafine for onychomycosis in Europe | Yes | PR | Exclusive | Top Pharma | Infectious-Miscellaneous | Fungal | Drug Delivery, Synthetics | Small Molecule, Topical | Europe | Enzyme Inhibitor | squalene monooxygenase | Inhibitor | EUR 1.5 million | EUR 50 million (US$56M) in milestone payments, including EUR 1.5 million (US$1.7M) paid at signing | |||||
83 | 02/2019 | Discovery | Morphic Therapeutics | Johnson & Johnson, Janssen | License, Option, Research | Oral integrin therapies for undisclosed indications | Yes | PR | Top Pharma | Synthetics | Small Molecule | Worldwide | Undisclosed upfront payment and research funding, and development, clinical and commercial milestones totaling over $725M. | ||||||||||||||
84 | 02/2019 | Phase I, Orphan Indication | Myeloproliferative Neoplasm Research Consortium, Mount Sinai | Forbius | Research | Phase I/II evaluation of AVID200 TGF-beta inhibitor in myelofibrosis | Yes | PR | Research Institution | Cancer | Other Cancer | Growth Factor | transforming growth factor (TGF) beta 1 (TGFB1), transforming growth factor (TGF) beta 3 (TGFB3) | Inhibitor | |||||||||||||
85 | 02/2019 | Phase I | Neurotrope | NIH, National Cancer Institute | Research | CRADA to evaluate Bryostatin-1 in Phase I trial for leukemia and B-cell lymphoma | Yes | PR | Research Institution | Cancer | Leukemia, Lymphoma | Synthetics | Small Molecule | ||||||||||||||
86 | 02/2019 | Phase II | Novartis | Anthos Therapeutics | Equity, License | Spinout of Anthos to develop MAA868 anti-Factor XI/XIa antibody for cardiovascular diseases | Yes | PR | Top Pharma | Cardiovascular | Arrhythmia | Monoclonals | |||||||||||||||
87 | 02/2019 | Phase II, Phase I, Preclinical | Shanghai HaiHe Biopharma | CSPC Pharmaceutical | Joint Venture | Joint venture to develop RMX1001, RMX1002, RMX2001, HH185 and CDK4/6i | Yes | PR | Autoimmune/Inflammatory, Central Nervous System, Infectious-Bacterial | Osteoarthritis, Pain, Rheumatoid Arthritis, Tuberculosis | Synthetics | Small Molecule | Enzyme Inhibitor, Receptor, Antibacterial | cyclooxygenase-2 (COX-2), prostaglandin E2 receptor EP4 subtype | Antagonist, Inhibitor | ||||||||||||
88 | 02/2019 | Phase III, Orphan Indication | 530.00 | SK Biopharmaceuticals | Arvelle Therapeutics | License | Cenobamate (YKP3089) for epilepsy in Europe | Yes | PR | Exclusive | Central Nervous System | Epilepsy | Synthetics | Small Molecule | Europe | Channel | sodium channel | Antagonist | Axovant will receive a 5% preferred equity stake in Arvelle | ||||||||
89 | 02/2019 | Preclinical, Orphan Indication | Sosei, Heptares Therapeutics | Inexia | Equity, License | Spin out of Inexia to develop preclinical intranasal small molecule orexin agonists for narcolepsy | Yes | PR | Central Nervous System | Sleep Disorders | Drug Delivery, Synthetics | Nasal, Small Molecule | |||||||||||||||
90 | 02/2019 | Preclinical, Orphan Indication | Sosei, Heptares Therapeutics | Orexia | Equity, License | Spin out of Orexia to develop oral small molecule orexin agonists for narcolepsy | Yes | PR | Central Nervous System | Sleep Disorders | Drug Delivery, Synthetics | Oral, Small Molecule | |||||||||||||||
91 | 02/2019 | Discovery | Sygnature Discovery | Pathios Therapeutics | Equity, License, Research | Integrated drug discovery program against G Protein-Coupled Receptor target | Yes | PR | Autoimmune/Inflammatory | Screening | |||||||||||||||||
92 | 02/2019 | Phase I | Syntrix | NIH | Research | $3.4M grant to support Phase I/II trial of SX-682 in myelodysplastic syndrome | Yes | PR | Research Institution | Cancer | Leukemia, Other Cancer | Synthetics | Small Molecule | Receptor | interleukin 8B receptor, interleukin 8A receptor | Antagonist | |||||||||||
93 | 02/2019 | Preclinical, Orphan Indication | 90.00 | Teneobio | AbbVie | License, Option | TNB-383B BCMA-targeting immunotherapeutic for multiple myeloma | Yes | PR | Exclusive | Top Pharma | Cancer | Multiple Myeloma | Monoclonals | Bispecific | Worldwide | |||||||||||
94 | 02/2019 | Discovery | University of Dundee | Takeda | Research | Small molecules targeting tau pathology | Yes | PR | Research Institution | Top Pharma | Central Nervous System | Alzheimer's Disease | Synthetics | Small Molecule | |||||||||||||
95 | 02/2019 | Preclinical, Orphan Indication | University of Pennsylvania | Passage Bio | License, Option, Research | Five AAV gene therapy products for rare monogenic CNS diseases, option to additional programs | Yes | PR | Research Institution | Other/Miscellaneous | Genetic Disorders | Oligonucleotides | Gene Therapy | ||||||||||||||
96 | 02/2019 | Discovery | 15.00 | Verseau Therapeutics | 3SBio | Equity, License | Macrophage checkpoint modulator antibodies for all human oncology indications in China | Yes | PR | Exclusive | Cancer | Broad Focus Cancer | Monoclonals | Asia | China | $15 million of Verseau Series B preferred stock | |||||||||||
97 | 02/2019 | Discovery | 65.00 | 1,445.00 | 4.50 | Voyager Therapeutics | AbbVie | Co-Development, License, Option, Research | AAV gene therapy to pathological species of alpha-synuclein for Parkinson's | Yes | SEC Redacted | Exclusive | 2013-19 IPOs | Top Pharma | Central Nervous System | Parkinson's Disease | Monoclonals, Oligonucleotides | Gene Therapy, Human Abs | Worldwide | $500M in agg sales milestones, per Voyager's 2/21/19 8-K | Mid-single digit royalty, per Voyager's 2/21/19 8-K | $80M for Research Compound, $75M on licesnse option exercise, plus $450M in dev/reg milestones for Parkinson's, per Voyager's 2/21/19 8-K | $30M for each of 3 add'l Research Compounds, plus $185M in dev/reg milestones for non-Parkinson's indication, per Voyager's 2/21/19 8-K | |||||||
98 | 02/2019 | Preclinical, Discovery | 120.00 | 460.00 | 26.09 | Xencor | Roche, Genentech | Co-Development, Co-Promotion, License, Option, Research | XmAb24306 (IL-15 cytokine) and add'l IL-15 compounds for cancer | Yes | Yes | SEC Redacted | Exclusive | 2013-19 IPOs | Top Pharma | Cancer | Broad Focus Cancer | Monoclonals | Bispecific | Worldwide | Immuno-Oncology | interleukin 15 (IL15) | Inhibitor | 45.00 | $160M in development milestones for the XmAb24306 program, per Xencor's 3Q19 | $180M in development milestones for each new IL-15 drug candidate, per Xencor's 3Q19 | 45% PS, per Xencor's 3Q19 | Xencor pays 100% of Initial Studies & 45% of dev costs after Initial Studies | ||
99 | 01/2019 | Discovery | Ablexis | Lilly | License | Expanded rights to AlivaMab Mouse platform for discovery of antibody-based therapeutics | Yes | PR | Non-exclusive | Top Pharma | Monoclonals, Transgenics | Transgenic mice | |||||||||||||||
100 | 01/2019 | Discovery | 300.00 | Adaptive Biotechnologies | Roche, Genentech | License, Research | TruTCR platform to develop neoantigen directed T-cell therapies for cancer | Yes | PR | Top Pharma | Cancer | Broad Focus Cancer | Cell Therapy - Stem Cells/Factors, Screening | Worldwide | Development, regulatory and commercial milestones in excess of $2 billion |